452105-38-3

Upstream product

• 141395-84-8 (2R)-(+)-N-(2,3-epoxypropyl)morpholine 
• 141395-85-9 (S)-1-Azido-3-morpholin-4-yl-propan-2-ol 

Downstream Products

• 135913-03-0 (S)-2-Benzyloxycarbonylamino-4-((R)-2-hydroxy-3-morpholin-4-yl-propylcarbamoyl)-butyric acid tert-butyl ester 
• 135970-78-4 (S)-2-Benzyl-N-((2R,8S,11S,12R)-11-cyclohexylmethyl-12-hydroxy-2-morpholin-4-ylmethyl-5,9,13-trioxo-1-oxa-4,10-diaza-cyclotridec-8-yl)-3-(2-methyl-propane-2-sulfonyl)-propionamide 
• 135970-68-2 [(S)-1-((2R,8S,11S,12R)-11-Cyclohexylmethyl-12-hydroxy-2-morpholin-4-ylmethyl-5,9,13-trioxo-1-oxa-4,10-diaza-cyclotridec-8-ylcarbamoyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 141395-91-7 (4S,5R)-4-Cyclohexylmethyl-2,2-dimethyl-oxazolidine-3,5-dicarboxylic acid 5-{(R)-1-[((S)-4-benzyloxycarbonylamino-4-tert-butoxycarbonyl-butyrylamino)-methyl]-2-morpholin-4-yl-ethyl} ester 3-tert-butyl ester 
• 135970-66-0 ((2R,8S,11S,12R)-11-Cyclohexylmethyl-12-hydroxy-2-morpholin-4-ylmethyl-5,9,13-trioxo-1-oxa-4,10-diaza-cyclotridec-8-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF

The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, espe

3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors

The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

The synthesis of potent marcocyclic renin inhibitors

An efficient synthesis of a novel class of potent macrocylic renin inhibitors exemplified by compounds 1 and 2, which involves the marcocyclization of 8 and 9 as the key step, is described. The macrocyclic design of renin inhibitors 1 and 2 disclosed here